Gastric cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 18, Issue SUPPL. 2, 2007, Pages

  Cunningham, D ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; FOLLOW UP; GASTRECTOMY; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RISK ASSESSMENT; STOMACH CANCER; TREATMENT PLANNING;

HUMANS; NEOPLASM STAGING; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 54349116210     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm019     Document Type: Article

References (11)

1. Roukos DH. Current status and future perspectives in gastric cancer management. Cancer Treat Rev 2000; 26: 243-255.
2. Macdonald JS, Smalley SR, Benedetti J et al, Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
3. Cunningham D, Allum WH, Stenning SP et al. Perioperative versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
4. Mari E, Floriani I, Tinazzi A et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomized trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 2000; 11: 837-843.
5. Janunger KG, Hafstrom L, Nygren P, Glimelius B. A systematc overview of chemotherapy effects in gastric cancer. Acta Oncol 2001; 40: 309-326.
6. Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-267.
7. Schuhmacher CP, Fink U, Becker K et al. Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer 2001; 91: 918-927.
8. Souglakos J, Syrigos K, Potamianou A et al. Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: A multicentre phase II trial. Ann Oncol 2004; 15: 1204-1209.
9. Jordan K, Kellner O, Kegel T et al. Phase II trial of capecitabine/ irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers. Clin Colorectal Cancer 2004; 4: 46-50.
10. Roth AD, Maibach R, Fazio N et al. 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxatere)-cisplatin in advanced gastric carcinoma: A phase I-II trial. Ann Oncol 2004; 15: 759-764.
11. Wagner AD, Grothe W, Behl S et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2: CD004064.